Introducing the new Regenerative Medicine aims and scope
In light of the 10-year anniversary of the award-winning journal Regenerative Medicine, Commissioning Editor Elena Conroy and Senior Editor Chris Mason are delight to announce an update to the journal’s aims and scope.
The field of regenerative medicine has undergone significant change in the last 10 years. We have grown mini organs, edited the genome of cells with specificity, grown organs from scaffolds, begun 3D printing tissues and much more. In light of this advancement, the Editors of Regenerative Medicine and Senior Editor Chris Mason have updated the scope to include the full breadth of modern regenerative medicine:
Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focuses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization.
Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community.
Regenerative Medicine exclusively supports all avenues that lead to the replacement or regeneration of human cells, tissue or organs, to restore or establish normal function. The sector is complex, rapidly evolving and multidisciplinary in nature, however, Regenerative Medicine is highly dynamic and has always embraced the progress made by the field and moved accordingly to support the critical issues including:
- Bench-to-bedside translation
- Tissue engineering and organ replacement
- Regenerative pharmacology
- Cell and gene therapy
- Regenerative nanotechnology
- Manufacturing and cost of goods
- Regulatory and reimbursement
- Ethical and legal perspectives
- Business models and commercialization
- Government policy
Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.
*Mason C. and Dunnill P. (2008) A brief definition of regenerative medicine. Regenerative Medicine. 3(1), 1-5.
The new scope will be officially presented at the World Stem Cell Summit it Atlanta this week. If you have any questions or are interested in submitting, please contact Commissioning Editor Elena Conroy (firstname.lastname@example.org) and if you're attending the conference, please come by to booth #211.